Home ยป
THOUSAND OAKS, Calif., Sept. 20, 2020 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that updated data from the full Phase 1 cohort of the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 129 patients across
Commercially available antivenoms in India can be ineffective in treating bites from certain medically important neglected snakes, a new study has shown. These snakes are those whose bites are harmful to humans, yet are poorly
Medication prescribed for a certain type of epilepsy may offer a new method for treating malignant infantile brain tumors. A specific mTOR inhibitor has the ability to cross the blood-brain barrier to both reach and
A new study from researchers at the Johns Hopkins Bloomberg School of Public Health found that in several cities and counties the proportion of high-schoolers who have ever used heroin or misused prescription opioids is
More than 14 million Americans suffer from clinical depression, yet one in three doesn’t experience relief from approved antidepressant drugs. A new treatment approach involving drugs called neurosteroids is on the horizon, however. Neurosteroids occur
Inside a labor room at Brigham and Women’s Hospital in Boston, nurses and physicians monitored Yingzi Lin’s vitals, checking on her over the course of three days, and asking how much pain she was feeling.
A research team from the School of Chinese Medicine at Hong Kong Baptist University (HKBU) has successfully developed a novel aptamer, i.e. a single-stranded piece of DNA, for the treatment of osteogenesis imperfecta (OI) with
The 2018 federal Right to Try Act allows patients with a life-threatening illness to be treated with drugs that have not yet been approved by the Food and Drug Administration (FDA). Many in the oncology
New research shows that a specific mind-body therapy, Mindfulness-Oriented Recovery Enhancement (MORE), increases the brain’s response to natural, healthy rewards while also decreasing the brain’s response to opioid-related cues. The study, published Wednesday in the
The health care market is failing to support new antibiotics used to treat some of the world’s most dangerous, drug-resistant “superbugs,” according to a new analysis by University of Pittsburgh School of Medicine infectious disease